Recent Evidence on the Use of Tiotropium Bromide in Pediatric Asthma: Summary Results of Eight Clinical Trials
Recent Evidence on the Use of Tiotropium Bromide in Pediatric Asthma: Summary Results of Eight Clinical Trials
Ricardo Cardona-Villa, MD, MSc1,2,*
Manuela Tejada-Giraldo, BioEngr, MSc11Grupo Alergología Clínica y Experimental (GACE), Universidad de Antioquia, Medellín, Colombia
*,2IPS Universitaria - Servicio de Alergología Clínica, Universidad de Antioquia, Carrera 51A No. 62-42, Medellin, Colombia
Purpose of Review To collect the existing information on tiotropium as an add-on treat-
ment for asthma in children and adolescents.
Recent Findings The use of tiotropium bromide in children between 1 and 6 years old.
Summary Asthma is a disease that can be difficult to control. For the treatment of this,
there is a combination of medications, but often complete control of the disease is not
achieved. The addition of tiotropium, a long-acting muscarinic antagonist, to treatment
with inhaled corticosteroids has been recommended to improve lung function in adults
and adolescents who have uncontrolled asthma. Here we present a review of the eight
clinical trials that show the use of tiotropium in pediatric patients with asthma. The results
demonstrate efficacy in improving lung function (evaluated with different parameters), in
both children and adolescents; it also shows the safety of the drug in short and long-term
uses.
DOI 10.1007/s40521-018-0194-0
Comentarios
Publicar un comentario